Pharmacoeconomics of voriconazole in the management of invasive fungal infections

References

• Arendrup M. Invasive fungal infections: past achievements and challenges ahead. Clin. Microbiol. Infect.15(7), 599–601 (2009).
   PubMedGoogle Scholar
• Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect.14(Suppl. 4), 5–24 (2008).
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Lewis R, Raad I, Kontoyiannis D. Phaeohyphomycosis in a tertiary care cancer center. Clin. Infect. Dis.48(8), 1033–1041 (2009).
   PubMed Web of Science ®Google Scholar
• Wingard J. Fungal infections after bone marrow transplant. Biol. Blood Marrow Transplant.5(2), 55–68 (1999).
   PubMedGoogle Scholar
• Carrillo-Munoz AJ, Quindos G, Lopez-Ribot JL. Current developments in anti-fungal agents. Cur. Med. Chem. – Anti-Infect. Agents3(4), 297–323 (2004).
   Google Scholar
• Glasmacher A, Prentice A, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol.21(24), 4615–4626 (2003).
   PubMed Web of Science ®Google Scholar
• Prentice A, Donnelly P. Oral antifungals as prophylaxis in haematological malignancy. Blood Rev.15(1), 1–8 (2001).
   PubMedGoogle Scholar
• Ascioglu S, de Pauw B, Meis J. Prophylaxis and treatment of fungal infections associated with haematological malignancies. Int. J. Antimicrob. Agents15(3), 159–168 (2000).
   PubMed Web of Science ®Google Scholar
• Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy survey. Eur. J. Clin. Microbiol. Infect. Dis.11(2), 99–109 (1992).
   PubMed Web of Science ®Google Scholar
• Groll A, Shah P, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect.33(1), 23–32 (1996).
   PubMed Web of Science ®Google Scholar
• Georgopapadakou N, Walsh T. Human mycoses: drugs and targets for emerging pathogens. Science264(5157), 371–373 (1994).
   PubMed Web of Science ®Google Scholar
• Slavin M, Fastenau J, Sukarom I, Mavros P, Crowley S, Gerth W. Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int. J. Infect. Dis.8(2), 111–120 (2004).
   PubMed Web of Science ®Google Scholar
• Fridkin S, Jarvis W. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev.9(4), 499–511 (1996).
   PubMed Web of Science ®Google Scholar
• Pauw BD, Walsh T, Donnelly J et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis.46(12), 1813–1821 (2008).
   PubMed Web of Science ®Google Scholar
• Maertens J, Boogaerts M. Fungal cell wall inhibitors: emphasis on clinical aspects. Curr. Pharm. Des.6(2), 225–239 (2000).
   PubMed Web of Science ®Google Scholar
• Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin. Investig. Drugs15(6), 579–602 (2006).
   PubMed Web of Science ®Google Scholar
• Torres H, Hachem R, Chemaly R, Kontoyiannis D, Raad I. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis.5(12), 775–785 (2005).
   PubMed Web of Science ®Google Scholar
• Vfend®, package insert. Pfizer Inc., NY, USA (2008).
   Google Scholar
• Fischbarg J. Mechanism of fluid transport across corneal endothelium and other epithelial layers: a possible explanation based on cyclic cell volume regulatory changes. Br. J. Ophthalmol.81, 85–89 (1997).
   PubMedGoogle Scholar
• Clancy C, Nguyen M. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis.17(8), 573–575 (1998).
   PubMed Web of Science ®Google Scholar
• Johnson L, Kauffman C. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36(5), 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Greenhalgh K, Eve M, Oliver S, Nichols D. The pharmacokinetics and safety of intravenous voriconazole – a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol.56(Suppl. 1), 2–9 (2003).
   PubMedGoogle Scholar
• Jurkunas U, Langston D, Colby K. Use of voriconazole in the treatment of fungal keratitis. Int. Ophthalmol. Clin.47(2), 47–59 (2007).
   PubMedGoogle Scholar
• Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet366(9495), 1435–1442 (2005).
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother.46(8), 2546–2553 (2002).
   PubMed Web of Science ®Google Scholar
• Berge M, Guillemain R, Boussaud V et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl. Infect. Dis.11(3), 211–219 (2009).
   PubMed Web of Science ®Google Scholar
• Trifilio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transpl.35(5), 509–513 (2005).
   PubMed Web of Science ®Google Scholar
• Mohammedi I, Piens MA, Padoin C, Robert D. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis.24(5), 358–360 (2005).
   PubMed Web of Science ®Google Scholar
• Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int. J. Antimicrob. Agents27(4), 274–284 (2006).
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother.50(4), 1570–1572 (2006).
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis.34(5), 563–571 (2002).
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis.46(2), 201–211 (2008).
   PubMed Web of Science ®Google Scholar
• Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis.50(1), 27–36 (2010).
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother.53(1), 24–34 (2009).
   PubMed Web of Science ®Google Scholar
• Imhof A, Schaer DJ, Schanz U et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med. Wkly136(45–46), 739–742 (2006).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis.46(3), 327–360 (2008).
   PubMed Web of Science ®Google Scholar
• Krueger KP, Nelson AC. Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies. ClinicoEconomics Outcomes Res.1, 35–43 (2009).
   PubMedGoogle Scholar
• Eiden C, Peyriere H, Cociglio M et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann. Pharmacother.41(5), 755–763 (2007).
   PubMed Web of Science ®Google Scholar
• Philips JA, Marty FM, Stone RM, Koplan BA, Katz JT, Baden LR. Torsades de pointes associated with voriconazole use. Transpl. Infect. Dis.9(1), 33–36 (2007).
   PubMed Web of Science ®Google Scholar
• Vandecasteele SJ, Van Wijngaerden E, Peetermans WE. Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole. Eur. J. Clin. Microbiol. Infect. Dis.23(8), 656–657 (2004).
   PubMed Web of Science ®Google Scholar
• Conlon JD, Dauenhauer M, Tonkovic-Capin V et al. Voriconazole-induced blistering in the setting of graft versus host disease: a report of 2 patients. J. Am. Acad. Dermatol.58(3), 484–487 (2008).
   PubMed Web of Science ®Google Scholar
• Rotstein C. Empiric antifungal therapy in neutropenic cancer patients. Curr. Infect. Dis. Rep.8(1), 7–13 (2006).
   PubMedGoogle Scholar
• Potter M. Strategies for managing systemic fungal infection and the place of itraconazole. J. Antimicrob. Chemother.56(Suppl. 1), i49–i54 (2005).
   PubMed Web of Science ®Google Scholar
• Rotstein C, Cragin L, Laverdiere M et al. Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults. Can. J. Infect. Dis. Med. Microbiol.19(3), 219–226 (2008).
   PubMedGoogle Scholar
• Johnson MD, Kleinberg M, Danziger L, Ostrosky-Zeichner L. Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions. Expert Opin. Pharmacother.6(15), 2617–2632 (2005).
   PubMed Web of Science ®Google Scholar
• Wingard JR, Herbrecht R, Mauskopf J, Schlamm HT, Marciniak A, Roberts CS. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl. Infect. Dis.9(3), 182–188 (2007).
   PubMed Web of Science ®Google Scholar
• Lewis JS, Boucher HW, Lubowski TJ, Ambegaonkar AJ, Day DL, Patterson TF. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacotherapy25(6), 839–846 (2005).
   PubMed Web of Science ®Google Scholar
• Dominguez-Gil A, Martin I, Garcia Vargas M, Del Castillo A, Diaz S, Sanchez C. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Clin. Drug Investig.27(3), 197–205 (2007).
   PubMed Web of Science ®Google Scholar
• Selleslag D, Vogelaers D, Marbaix S. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium. Acta Clin. Belg.64, 393–398 (2009).
   PubMed Web of Science ®Google Scholar
• Jansen JP, Kern WV, Cornely OA et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health9(1), 12–23 (2006).
   PubMed Web of Science ®Google Scholar
• Jansen JP, Meis JF, Blijlevens NM, van’t Wout JW. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in The Netherlands. Curr. Med. Res. Opin.21(10), 1535–1546 (2005).
   PubMed Web of Science ®Google Scholar
• Greene RE, Mauskopf J, Roberts CS, Zyczynski T, Schlamm HT. Comparative cost–effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. Am. J. Health Syst. Pharm.64(24), 2561–2568 (2007).
   PubMed Web of Science ®Google Scholar
• Mesrobian X, Loftus J, Roberts C et al. Cost–effectiveness of voriconazole versus liposomal amphotericin B for invasive aspergillosis infection in the UK. Value Health8, A20 (2005).
   Google Scholar
• Ament AJ, Hubben MW, Verweij PE et al. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in The Netherlands: a modelling approach. J. Antimicrob. Chemother.60(2), 385–393 (2007).
   PubMed Web of Science ®Google Scholar
• Rotstein C, Laverdiere M, Marciniak A, Ali F. An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada. Can. J. Infect. Dis. Med. Microbiol.15(5), 277–284 (2004).
   PubMedGoogle Scholar
• Wenzel R, Del Favero A, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J. Antimicrob. Chemother.55(3), 352–361 (2005).
   PubMed Web of Science ®Google Scholar
• Garbino J, Schnetzler G, Roberts C. Invasive aspergillosis: is treatment with ‘inexpensive’ amphotericin B cost saving if ‘expensive’ voriconazole is only used on demand? Swiss Med. Wkly136(39–40), 624–630 (2006).
   PubMedGoogle Scholar
• Marbaix S, Marciniak A, De Mees V et al. Cost–effectiveness of voriconazole compared with conventional amphotericin B in first line treatment of invasive aspergillosis in Belgium. Value Health6, 750 (2003).
   Google Scholar
• Grau S, Mateu-de Antonio J, Soto J, Munoz M, Salas E. Cost–effectiveness analysis of voriconazole versus amphotericin B in the treatment of invasive aspergillosis in Spain. Value Health6, 750 (2003).
   Google Scholar
• Riedel A, Choe L, Inciardi J, Yuen C, Martin T, Guglielmo BJ. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect. Dis.7, 70 (2007).
   PubMed Web of Science ®Google Scholar
• Al-Badriyeh D, Slavin M, Liew D et al. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. J. Antimicrob. Chemother.65(5), 1052–1061 (2010).
   PubMed Web of Science ®Google Scholar
• Collins CD, Ellis JJ, Kaul DR. Comparative cost–effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am. J. Health Syst. Pharm.65(23), 2237–2243 (2008).
   PubMed Web of Science ®Google Scholar
• Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy27(7), 970–979 (2007).
   PubMedGoogle Scholar
• Slobbe L, Polinder S, Doorduijn JK et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin. Infect. Dis.47(12), 1507–1512 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Badriyeh D, Liew D, Stewart K, Kong DC. Cost–effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J. Antimicrob. Chemother.63(1), 197–208 (2009).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347(6), 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med.340(10), 764–771 (1999).
   PubMed Web of Science ®Google Scholar
• Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J. Antimicrob. Chemother.64(6), 1274–1281 (2009).
   PubMed Web of Science ®Google Scholar
• Van Campenhout H, Marbaix S, Derde MP et al. Voriconazole treatment of invasive aspergillosis: real world versus health-economic model results. Clin. Drug Investig.28, 509–521 (2008).
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis.39(6), 797–802 (2004).
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye AP, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation81(3), 320–326 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas A, Korb V, Guillemain R et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J. Clin. Pharm. Ther.35(1), 49–53 (2010).
   PubMedGoogle Scholar
• Bennett J, Powers J, Walsh T et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin. Infect. Dis.36(Suppl. 3), S117–S122 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med.346(4), 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Nixon J, Stoykova B, Glanville J, Christie J, Drummond M, Kleijnen J. The U.K. NHS economic evaluation database. Economic issues in evaluations of health technology. Int. J. Technol. Assess. Health Care16(3), 731–742 (2000).
   PubMed Web of Science ®Google Scholar
• Powers JH, Dixon CA, Goldberger MJ.Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N. Engl. J. Med.346(4), 289–290 (2002).
   PubMed Web of Science ®Google Scholar
• Husain S, Paterson DL, Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant.6(12), 3008–3016 (2006).
   PubMed Web of Science ®Google Scholar
• Cadena J, Levine DJ, Angel LF et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am. J. Transplant.9(9), 2085–2091 (2009).
   PubMed Web of Science ®Google Scholar
• van-der-Linder J, Jansen RR, Bresters D et al. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis.48, 1111–1113 (2009).
   PubMedGoogle Scholar